Asia-Pacific · raised · biotech
Zumutor dosed the first patient with its anti-LLT1 antibody in a Phase 1 trial at Dana-Farber in June 2024.
Zumutor Biologics runs a Phase 1 trial of its anti-LLT1 antibody at Dana-Farber and other US sites, with first dosing in June 2024. The company closed a $7.3 million round that included PremjiInvest and Accel.